Home › Multiple Myeloma › Wisconsin › Madison
Multiple Myeloma clinical trials in Madison, WI
9 studies for Multiple Myeloma are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Madison
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPhase 1/2
- University of Wisconsin Carbone Cancer Center, Madison
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
RecruitingPhase 1/2
- University of Wisconsin, Madison
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center-University Hospital, Madison
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
RecruitingPhase 3
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RecruitingPhase 2
- University of Wisconsin - Carbone Cancer Center, Madison
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RecruitingPhase 3
- University of Wisconsin Hospital and Clinics, Madison
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
RecruitingPhase 2
- University of Wisconsin Clinical Science Center, Madison
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer22 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Lung Cancer10 studies
- Pancreatic Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.